Structural and Functional Characterization of Liposomal Recombinant Hepatitis B Vaccine
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 6 (2) , 289-304
- https://doi.org/10.3109/08982109609031118
Abstract
Liposomal hepatitis B vaccine was prepared by encapsulating recombinant 22-nm hepatitis B surface antigen (HBsAg) particles derived from a Chinese hamster ovary (CHO) cell line in multilammelar lipid vesicles (MLV) composed of 9:1 dimyristoyl phosphatidyl-choline/dimyristoyl phosphatidylglycerol. The CHO-derived HBsAg particles reveal 6 bands in polyacrylamide gel electrophoresis related to the presence of 3 peptides (S, M, & L). Four different methods were used to prepare the MLV vaccine, each resulting in freeze-dried powder which upon hydration gave MLV of a similar mean size, 4.5 μm. The humoral response to these 4 liposomal vaccines in mice was dependent on the method of preparation, but for all of them it was better than the response to alum-based vaccine (especially at a low dose of antigen). Comparison of vaccination using “naked” HBsAg particles, particles adsorbed to alum, and particles encapsulated in liposomes demonstrated that at low dose of antigen the liposomal vaccine was superior in eliciting humoral response. Encapsulation in liposomes did not improve specific cytotoxic T lymphocyte (CTL) response. The alum in the vaccine completely eliminates CTL response, though it improved the humoral response by increasing the linear range in the antigen dose-response curve (increasing the antibody titer at high antigen dose). A similar response profile was obtained with recombinant yeast (Hansenula) 22-nm particles composed of a single non-glycosylated (p24) peptide and lipids. The similarity in the response to the mammalian cell and yeast derived vaccine suggests that the physical nature of the vaccine, more than the exact composition, determines the balance between humoral and CTL responses.Keywords
This publication has 21 references indexed in Scilit:
- Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigenEuropean Journal of Immunology, 1994
- Clinical Experience with the PreS1-containing Hepatitis B Vaccine (HG-3) in Different Nonresponder GroupsPublished by Springer Nature ,1994
- Immunogenicity of a Mammalian Cell-derived Recombinant Hepatitis B Vaccine Containing Pre S2 and Pre S1 Antigens: A Preliminary ReportPublished by Springer Nature ,1994
- Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccinesVaccine, 1994
- Preparation and Characterization of Stable Liposomal Hepatitis B VaccinePublished by Springer Nature ,1993
- Immunologic Presentation of Liposomal AntigensJournal of Liposome Research, 1993
- Liposomes as carriers of antigens and adjuvantsJournal of Immunological Methods, 1991
- Recombinant-yeast-derived hepatitis b vaccine in healthy adults: Safety and two-year immunogenicity of early investigative lots of vaccineJournal of Medical Virology, 1989
- Novel hepatitis B vaccinesJournal of Infection, 1986
- Characterization of large surface proteins of hepatitis B virus by antibodies to preS-S encoded amino acidsVirology, 1986